Supplementary Methods from Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models
Open Access
- 3 April 2023
- other
- Published by American Association for Cancer Research (AACR)